Navigation Links
Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
Date:5/20/2011

the hand.(1) It affects approximately 3-13% of the European population.(2) The disease starts in the palm of the hand with the appearance of a number of small lumps (called nodules), made of cells that can produce abnormal deposits of collagen.(1) As the disease progresses, excess collagen continues to build up and may eventually form into a rope-like cord under the skin.(1) The cord extends from the palm into the finger and can gradually contract or bend the finger permanently toward the palm, known as Dupuytren's contracture.(1) Once contracture has occurred, the affected finger often interferes with the patient's ability to carry out everyday tasks.(1)

About XIAPEX (Collagenase clostridium histolyticum)

Collagenase clostridium histolyticum is a combination of two purified collagenases (collagenase is an enzyme capable of breaking down collagen), derived from the bacterium Clostridium histolyticum.  It is the first pharmacological treatment to be developed for Dupuytren's contracture and may be an alternative to invasive and often complicated surgery for patients in the EU.  Collagenase clostridium histolyticum is administered by local injection directly into the Dupuytren's cord – a procedure which can be carried out in an outpatient setting.  It works by breaking down the structure of the cord and, 24 hours after injection, a finger extension procedure can be carried out as necessary to break the cord and allow extension of the finger.  If contracture remains four weeks after treatment, another injection can be administered into the same cord, and the finger extension procedure can be carried out again.  Injections and finger extension procedures may be administered up to three times per cord, at approximately four-week intervals.

Further details and product information will be available in the European Public Assessment Report on the web site of the European Medicines Agency at www.emea.europa.eu.


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
2. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
3. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
4. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
7. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
8. ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010
9. Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
10. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
11. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is ... Research Grant program. LOIs are due no later than ... Discovery Grants are one-year, $50,000 grants that fund ... current diagnostic or treatment paradigms for adults and children ... at its earliest stages, in the hopes that it ...
(Date:9/1/2015)... , Sept. 1, 2015 Prostate ... death in American men. One in seven ... 233,000 new cases are diagnosed annually. That said, ... using a powerful new technique, MRI Fusion Biopsy, ... large cancer lesions, treating only the affected areas ...
(Date:9/1/2015)... ... September 01, 2015 , ... In her thought provoking debut novel ‘ Ebola ... not-so-distant future faced with an Ebola pandemic that is on the cusp of wiping ... enter the world of counterterrorism, and who continues to appear in this series of ...
Breaking Biology Technology:Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3
... CHAGRIN FALLS, Ohio, July 8 Knowledge ... today the release of The,2007-2008 Orthopaedic Industry ... strategically oriented industry data. The nearly 200,page ... through,sections dedicated to Joint Replacement, Fracture Repair, ...
... First Organ-specific MRI Contrast Agent Approved in the United States in ... ... July 8 Bayer HealthCare Pharmaceuticals,Inc., a leader in diagnostic imaging, ... EOVIST(R) (Gadoxetate Disodium),Injection, a gadolinium-based contrast agent, for intravenous use in,T1-weighted ...
... Maintain ... Commitment to Strategy, VANCOUVER ... OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, has ... purpose of acquiring control of MIGENIX,s board of directors (see,"Requisition ...
Cached Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8
(Date:8/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... The Smart Card Alliance and the EMV Migration Forum.  ... the Smart Card Alliance Latin America (SCALA) Chapter provides ... and thought leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... ,e-SMART(R) Technologies, Inc., (Pink Sheets: ESMT); with its parent ... pleased to,announce that it has signed a contract to ... the SamWon FA Co., Ltd., in Seoul, South,Korea., ... network),company in South Korea and a leading manufacturer of ...
... discovered how roots find their way past obstacles to grow ... Science, also explains how germinating seedlings penetrate the soil without ... in the fuzzy coat of hairs on the roots of ... control mechanism that enables these hairs to find their way ...
... important discovery has been made with respect to the mystery ... research professor at Arizona State University, found that some of ... Earth have been shown to carry handedness in a larger ... in this weeks Early Edition of the Proceedings of the ...
Cached Biology News:e-SMART Technologies Continues Delivery of Its New Super SMART Card in South Korea 2ASU researcher may have discovered key to life before its origin on Earth 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: